Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …
Biotechnology
US, Cambridge [HQ]
Strategy & Leadership
Mergers & Acquisitions Beta
M&A Details · Industry · Urgent
M&A Deals · Breakdown
Intellia Therapeutics, Inc. has no acquisition track records yet.
M&A Deals · History
Intellia Therapeutics, Inc. has no acquisition track records yet.
M&A Deals · Within Industry
No current deals within Biotechnology Industry.
M&A Deals · Latest
Act, dont react; Track the most urgent M&A deals across all industries
Details
Details
Details
?
Equity
Agg. Maximum Price
$4,221.65
?
Details
Details
United Bankshares, Inc.
Equity
Agg. Maximum Price
$206,633,909.86
?
Details
Details
Details
Icahn Enterprises L.P.
Debt
Agg. Maximum Price
$700,000,000.00
?
Details
Details
Corebridge Financial, Inc.
Debt
Agg. Maximum Price
$500,000,000.00